Many ppl thinking Astro is sunset company but actually like Malaysia's version of Netflix or Disney+

BAT at RM10 is very very cheap with 10%Div, at RM20 is very cheap with 5%, at RM30 is cheap, at RM40 etc...

BAT fly like Batman is return and hope not so fast caused we need to fasten belt and safety first. Well done.

UK get vaccination next week while US get by mid Dec both signing good opp to Genting operation in both countries. Well done.

glove counter nowadays not news is good news even though quarterly result.

BAT wanted to set up conglomerate company and will build vape, vaccines and cigarettes factory in Malaysia since gov so support them now.

Why need to wait for 11 vaccines to come online, just Moderna vaccine alone can get 100% efficacy to cure severe covid infection. Yes, my word is real, 100% mean 100%. Moderna just need to issue franchise to all vaccines manufacturing company to produce 6bil dose per month enough to end the outbreak.

Just Dec alone 2 vaccines company enough to supply first dose of 70mil vaccines to US ppl which is one-third of population. Once the vaccines prove working well in next 2 months all ppl will rushing to get vaccinated.

let make the vaccines cost usd500 and only 50% effective, we still wanted to take it. Better then cost of doing testing, mask, glove and social distance which not even to prove really working 100% as well.

Mask, glove, ppe, etc all need to pay money but vaccines gov give free for all Malaysian so good and perfect.

The Covid-19 vaccine by Pfizer and BioNTech cost RM79.36 per dose. So cheap, we should buy more to support 100% population.

https://www.theedgemarkets.com/article/health-dg-malaysias-agreement-pfizer-will-be-void-if-covid19-vaccine-fails-be-registered-fda

The Covid-19 vaccine by Pfizer and BioNTech cost RM79.36 per dose. So cheap, we should buy more to support 100% population.

https://www.theedgemarkets.com/article/health-dg-malaysias-agreement-pfizer-will-be-void-if-covid19-vaccine-fails-be-registered-fda

Muhyiddin said a recent study by YouGov, a British international Internet-based market research and data analytics firm, found that 82% of Malaysians are ready to be vaccinated

https://www.theedgemarkets.com/article/covid19-vaccine-be-given-free-malaysians-says-pm-muhyiddin

https://www.theedgemarkets.com/article/covid19-msia-negotiating-10-companies-vaccine-%E2%80%94-pm-muhyiddin

https://www.theedgemarkets.com/article/malaysias-covid19-vaccine-first-recipients-not-lab-rats-%E2%80%94-pm-muhyiddin

Most defensive stock in the world regardless pandemic, air pollution, flood, politics etc

Not nd to ask more just 20cent dividends every quarter enough to make investor smile. Imaging every year U investment will automatic increase 80cent how nice is that.

Management gave the keyword in the report-

"The lower revenue from Resorts World Genting (“RWG”) in the current quarter was mainly due to lower business volume from the general market and non-gaming segments as the resort continues to operate with reduced capacity. The volume of business from the mid to premium players segment was relatively the same as that in the previous year’s corresponding quarter despite the lower capacity."

As long as casino open there is the profit to be.

RWG, RWS and GENP show good result but off set by operation in UK and US. Once vaccination take place soon all will back to profit. Good job.

Genting hv RM32Bil cash in hand. Neither share buyback (already hv 221mil treasury shares) nor venture into glove or PPE sector due to management vision to the long term business policy instead of short term speculation. Although such tough business environment but not ever shake it cash balance at all, truly too big to fail.

https://www.theedgemarkets.com/article/employee-resorts-world-genting-tested-positive-covid19

Only 1 case also making big news!

Genting always take the necessary precautionary measures as the health and safety of all guests and employees have always been they priority.

No worry vaccines will safe glove soon.

KUALA LUMPUR (Nov 25): The 70% target of Malaysian population to get the Covid-19 vaccine in the first quarter of 2021, will focus on adults to enable the country to reach the herd immunity threshold, said Science, Technology and Innovation Minister Khairy Jamaluddin.

He said if the herd immunity threshold is achieved, those who have not been vaccinated would be protected from Covid-19 infection.

"There will be some who will not get the vaccination because most of the Covid-19 vaccines developed have not been tested on children under the age of 12, so definitely they will not be vaccinated next year.
Sponsored Content

"So this will probably be the non-vaccinated percentage, we will concentrate of the adult group in achieving herd immunity,” he said when winding up the debate of the Supply Bill 2021 at the Dewan Rakyat sitting today.

He said the government would not compromise on health and safety and would obtain the preliminary and interim safety data so that Malaysians are not made laboratory rats.

He said the government would examine the clinical data provided by companies producing the vaccine especially those developing the Covid-19 vaccine for procurement.

"According to current plans, we will be able to get hold of the first vaccine in the first quarter of next year and an announcement will soon be made by Prime Minister Tan Sri Muhyiddin Yassin," he said.

Responding to Lim Lip Eng’s (PH-Kepong) interjection on the country's selection criteria for the procurement of Covid-19 vaccine, Khairy said the ministry was in talks with companies from several countries including the United States, Russia and China to determine the vaccine with the best portfolio for Malaysia.

He said before the vaccine procurement, studies were made on whether the vaccines provided sterilising immunity to protect against the infection or just to prevent serious spread of infection.

Khairy also informed that an independent Covid-19 vaccine evaluation committee has been set up under the Covid-19 Vaccine Access Guarantee Special Committee, chaired by epidemiologist Prof Datuk Dr Awang Bulgiba Awang Mahmud, comprising nine members with various expertise such as virology, molecular immunology and infectious diseases.

“We have taken this approach so that in determining the vaccines, we will seek this independent expert advice, to ensure that decisions are not based on any ministry’s recommendation,” he said in reply to Dr Dzulkefly Ahmad (PH-Kuala Selangor) who asked who were involved in the vaccine procurement.

Good dividend received. Not nd to chasing the price. Just relax and enjoy.

The outbreak really smash Airasia painfully. NTA cut to RM0.35 only, truly peer into bone. What could be left for next quarter and how long need to take to recover.

Look like vaccines still the safest to protect the virus. Imagine that u wear glove or mask however the glove or mask u use already infected with the virus for example the glove made from TOP GLOVE. U should be safest by not to wear it.

Genting hv RM32Bil cash in hand. Neither share buyback (already hv 221mil treasury shares) nor venture into glove or PPE sector due to management vision to the long term business policy instead of short term speculation. Although such tough business environment but not ever shake it cash balance at all, truly too big to fail.

On Nov. 23, AstraZeneca and Oxford announced that the vaccine had good efficacy, based on a study of the first 131 cases of Covid-19 in the trials in the United Kingdom and Brazil. The volunteers all got two doses, but in some cases the first dose was only half strength. Surprisingly, an initial half-strength dose led to 90 percent efficacy, while two standard-dose shots led only to 62 percent efficacy. The researchers speculated that the lower first dose did a better job of mimicking the experience of an infection, promoting a stronger immune response.

The preliminary analysis also indicated that the vaccine didn’t just reduce cases of Covid-19 with symptoms. It also reduced the number of asymptomatic cases. That finding may mean that the vaccine will be good at reducing the transmission of the virus from person to person. Another advantage of the vaccine is that it can be kept in a refrigerator, unlike Pfizer and Moderna’s vaccines, which have to be frozen.

Starting in May, AstraZeneca secured a series of agreements to provide vaccines to governments should they prove effective. The United States awarded the project $1.2 billion in support for 300 million doses. In August the European Union reached an agreement for AstraZeneca to deliver 400 million doses if the trials yield positive results. The company has said their total annual manufacturing capacity for the vaccine, if approved, stands at two billion doses.

On Nov. 23, AstraZeneca and Oxford announced that the vaccine had good efficacy, based on a study of the first 131 cases of Covid-19 in the trials in the United Kingdom and Brazil. The volunteers all got two doses, but in some cases the first dose was only half strength. Surprisingly, an initial half-strength dose led to 90 percent efficacy, while two standard-dose shots led only to 62 percent efficacy. The researchers speculated that the lower first dose did a better job of mimicking the experience of an infection, promoting a stronger immune response.

The preliminary analysis also indicated that the vaccine didn’t just reduce cases of Covid-19 with symptoms. It also reduced the number of asymptomatic cases. That finding may mean that the vaccine will be good at reducing the transmission of the virus from person to person. Another advantage of the vaccine is that it can be kept in a refrigerator, unlike Pfizer and Moderna’s vaccines, which have to be frozen.

Starting in May, AstraZeneca secured a series of agreements to provide vaccines to governments should they prove effective. The United States awarded the project $1.2 billion in support for 300 million doses. In August the European Union reached an agreement for AstraZeneca to deliver 400 million doses if the trials yield positive results. The company has said their total annual manufacturing capacity for the vaccine, if approved, stands at two billion doses.

On Nov. 23, AstraZeneca and Oxford announced that the vaccine had good efficacy, based on a study of the first 131 cases of Covid-19 in the trials in the United Kingdom and Brazil. The volunteers all got two doses, but in some cases the first dose was only half strength. Surprisingly, an initial half-strength dose led to 90 percent efficacy, while two standard-dose shots led only to 62 percent efficacy. The researchers speculated that the lower first dose did a better job of mimicking the experience of an infection, promoting a stronger immune response.

The preliminary analysis also indicated that the vaccine didn’t just reduce cases of Covid-19 with symptoms. It also reduced the number of asymptomatic cases. That finding may mean that the vaccine will be good at reducing the transmission of the virus from person to person. Another advantage of the vaccine is that it can be kept in a refrigerator, unlike Pfizer and Moderna’s vaccines, which have to be frozen.

Starting in May, AstraZeneca secured a series of agreements to provide vaccines to governments should they prove effective. The United States awarded the project $1.2 billion in support for 300 million doses. In August the European Union reached an agreement for AstraZeneca to deliver 400 million doses if the trials yield positive results. The company has said their total annual manufacturing capacity for the vaccine, if approved, stands at two billion doses.

On Nov. 23, AstraZeneca and Oxford announced that the vaccine had good efficacy, based on a study of the first 131 cases of Covid-19 in the trials in the United Kingdom and Brazil. The volunteers all got two doses, but in some cases the first dose was only half strength. Surprisingly, an initial half-strength dose led to 90 percent efficacy, while two standard-dose shots led only to 62 percent efficacy. The researchers speculated that the lower first dose did a better job of mimicking the experience of an infection, promoting a stronger immune response.

The preliminary analysis also indicated that the vaccine didn’t just reduce cases of Covid-19 with symptoms. It also reduced the number of asymptomatic cases. That finding may mean that the vaccine will be good at reducing the transmission of the virus from person to person. Another advantage of the vaccine is that it can be kept in a refrigerator, unlike Pfizer and Moderna’s vaccines, which have to be frozen.

Starting in May, AstraZeneca secured a series of agreements to provide vaccines to governments should they prove effective. The United States awarded the project $1.2 billion in support for 300 million doses. In August the European Union reached an agreement for AstraZeneca to deliver 400 million doses if the trials yield positive results. The company has said their total annual manufacturing capacity for the vaccine, if approved, stands at two billion doses.

Look like vaccines still the safest to protect the virus. Imagine that u wear glove or mask however the glove or mask u use already infected with the virus for example the glove made from TOP GLOVE. U should be safest by not to wear it.

Look like vaccines still the safest to protect the virus. Imagine that u wear glove or mask however the glove or mask u use already infected with the virus for example the glove made from TOP GLOVE. U should be safest by not to wear it.

Cambodia airport already fully open up for travel and receive huge number of passenger especially during china long holiday.

Now we are in the transition point or initial recovering stage and within next few month will clearly see travel open up and no more social distancing/PPE needed.

We aren't worry about when vaccines coming but more worry if outbreak end after vaccines just in the production line. very shameful.

In short we don't have sars and mers vaccines simply caused by virus just defeated before per-clinical trial. Now their species returned with pandemic outbreak and we already reached the last stage of clinical trial 3 with more than 90% efficiency. Sooner our life will be normal.

Seventeen years after the severe acute respiratory syndrome (Sars) outbreak and seven years since the first Middle East respiratory syndrome (Mers) case, there is still no coronavirus vaccine despite dozens of attempts to develop them.

As research institutes and companies around the world race to find potential vaccines for a new coronavirus strain that has infected nearly 80,000 people and claimed more than 2,000 lives, the question is, will this time be different?

Communicable disease outbreaks are handled by stopping transmission and with medicines and vaccines, but developing those vaccines takes time as they have to go through trials to ensure they are safe and effective.

They are also costly. According to Michael Osterholm, director of the Centre for Infectious Disease Research and Policy at the University of Minnesota, it can cost as much as US$1 billion to develop, licence and manufacture a vaccine from scratch – including building a facility to produce it in.
The new coronavirus strain originated in the central Chinese city of Wuhan in December and causes a disease known as Covid-19. Two previous coronavirus outbreaks – Sars and Mers – also had scientists trying to find vaccines.

For Sars in 2003, it took four months before the genome sequence of the coronavirus was available to develop antigens that could be used for animal and cell culture trials.
The first human trial of a possible Sars vaccine was conducted in Beijing in December 2004, but by that time the epidemic was over, and research into other diseases was given priority so it was shelved.

But the initial stage of the process has moved much faster for the new coronavirus than it did for Sars and Mers. Chinese researchers quickly isolated the strain and the genome sequence was released to the scientific community on January 10. That was well before the Chinese government announced the virus could be transmitted between humans, on January 21.
Funding also appears to be available, at least at this stage. With Beijing under huge pressure to control the epidemic that has stalled the economy for weeks, it has been willing to mobilise any resources it has for scientific research, and a special task force has been set up to coordinate efforts.

“Since the task force was set up, vaccine development has been a priority and we have pulled together all the best units in the country to work towards a breakthrough and to expedite the development of a vaccine,” Zhang Xinmin, director of the China National Centre for Biotechnology Development under the Ministry of Science and Technology, told the media on February 15.
Outside China, the Coalition for Epidemic Preparedness Innovations (CEPI) – a group backed by the Bill & Melinda Gates Foundation, the Wellcome Trust and investments from various countries to speed up vaccine development – is funding institutes and companies including US firm Inovio Pharmaceuticals, a joint project by US firm Moderna and the US National Institute of Allergy and Infectious Diseases, and the University of Queensland.

CEPI wants to see if new platform technologies – which allow vaccines for different viruses to be developed in the same platform after some adjustments – can be applied to vaccine development for the new coronavirus, reducing the production time. The concept is similar to the one used in developing new seasonal influenza vaccines.

Less than two months after the new strain was identified on January 7, several institutes in China, the United States and Europe have already begun animal trials.

According to the World Health Organisation (WHO), five vaccine candidates have reached the preclinical stage, which involves cell culturing and animal trials to find out if they can induce immunity.

Of the 33 vaccine candidates for Sars, only two reached clinical trials on humans, the rest stopped at the preclinical stage. For Mers, just three of the 48 vaccine candidates went to clinical trials on humans while the others only made it to the preclinical stage.

Given that Sars disappeared after 2003, some have questioned whether it is worthwhile to pour money into vaccine development for another coronavirus. According to scientists, that depends on whether it comes back.

“If the epidemic is only for this year, then the answer is no. But if Covid-19 recurs, then the answer is yes,” said Stanley Plotkin, who had a key role in developing the rubella vaccine in the 1960s and is now a consultant for vaccine companies, as well as on the specialist panel advising the WHO.
Smith said if there was no recurrence next year it would be difficult to obtain data to test the efficacy of vaccine candidates in human trials.

“If conventional control procedures stop transmission of the new virus in the next few months then it may be that vaccine studies to establish efficacy in human populations will not be possible [until there is another outbreak],” he said.

so many vaccines, just pick 1 that u like most. Protein flavor, mRNA ingredient or full flavor.

https://www.theedgemarkets.com/article/sinopharm-jvco-sponsor-10000-doses-covid19-vaccine-front-liners

We neither ur enemy nor ur friend just a retail investor. And you need to know the game of big player like EPF that they need to buy those share to short their position which make the price go down further when this kind of bad news came up in order to make a huge profit. They can build long or short position to make money but this is not our game.

Moderna's vaccine to be more than 94.5% effective on phase 3 trial which is by right this is what the purpose of stage 3 clinical trial to test the effective of the vaccine. If a student pass the exam with 94.5% score is very sure he/she is a excellent student. There is no doubt with the result of the vaccine and why it can produce such result in short period of time because this is a pandemic outbreak with mil of ppl get infected which scientist can roll out enough testing to find out the best cure for the disease.

Moderna's vaccine to be more than 94.5% effective on phase 3 trial which is by right this is what the purpose of stage 3 clinical trial to test the effective of the vaccine. If a student pass the exam with 94.5% score is very sure he/she is a excellent student. There is no doubt with the result of the vaccine and why it can produce such result in short period of time because this is a pandemic outbreak with mil of ppl get infected which scientist can roll out enough testing to find out the best cure for the disease.

A lot ppl dont this share link to an airport which operated in Cambodia.

Our dream finally come truth for 2021 that no need to see Donald Trump anymore. Virus kill him.

vaccine=virus and we make virus inject into our body sound crazy. But the truth is our body itself has the ability to fight and defeat the virus. The only country now undergo herd immunity is USA which 15% out of 300mil population already get infected with the virus. And this superpower country really show to the world the victory of war need to sacrifice the civilians. They proved to the world that mask, lock down and isolation aren't their choice.

Pfizer vaccine to be more than 90% effective on phase 3 trial which is by right this is what the purpose of stage 3 clinical trial to test the effective of the vaccine. If a student pass the exam with 90% score is very sure he/she is a excellent student. There is no doubt with the result of the vaccine and why it can produce such result in short period of time because this is a pandemic outbreak with mil of ppl get infected which scientist can roll out enough testing to find out the best cure for the disease.

Pfizer vaccine to be more than 90% effective on phase 3 trial which is by right this is what the purpose of stage 3 clinical trial to test the effective of the vaccine. If a student pass the exam with 90% score is very sure he/she is a excellent student. There is no doubt with the result of the vaccine and why it can produce such result in short period of time because this is a pandemic outbreak with mil of ppl get infected which scientist can roll out enough testing to find out the best cure for the disease.

Pfizer vaccine to be more than 90% effective on phase 3 trial which is by right this is what the purpose of stage 3 clinical trial to test the effective of the vaccine. If a student pass the exam with 90% score is very sure he/she is a excellent student. There is no doubt with the result of the vaccine and why it can produce such result in short period of time because this is a pandemic outbreak with mil of ppl get infected which scientist can roll out enough testing to find out the best cure for the disease.

genting link to genting singapore which up 8% sure will follow

Few threaten already pass on genting like tax high for budget 2021 and lock down while nw kick out of klse index look impossible also.

RWS Q3 result out with profit 54mil mean Genting already get RM70mil profit attributable to Equity holders. Now wait for RWG and GenP.